A next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. This 39-amino acid synthetic peptide represents the most comprehensive approach to metabolic regulation, offering superior weight loss and metabolic benefits.
A dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that provides superior weight loss and glycemic control compared to single-target therapies. Represents the next generation of metabolic peptides.
A long-acting GLP-1 receptor agonist that mimics the incretin hormone GLP-1. Originally developed for diabetes management, it's now widely used for weight loss due to its ability to slow gastric emptying, reduce appetite, and improve glucose metabolism.
A long-acting amylin receptor agonist designed for weekly dosing. Mimics the natural hormone amylin to enhance satiety, slow gastric emptying, and support weight management. Shows powerful synergy when combined with GLP-1 agonists.
